This content is machine translated Relapsing-remitting multiple sclerosis (RRMS) New S1P1 modulator expands the therapeutic spectrum The selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod has been approved in Switzerland since November 2021 for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease. The approval is…
